122 completed, 66 recruiting, 43 terminated, 26 active not recruiting. 134 Phase 1, 119 Phase 2, 23 Not applicable, 17 Phase 3, 9 Early Phase 1.
Follow this condition Literature Review of Non-Hodgkin Lymphoma trials Research Report on Non-Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma BAFF CAR-T - Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory | Phase 2 | Not yet recruiting | Luminary Therapeutics | 90 | 2026-12-01 | 2026-08-18 |
| Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity 68Ga-Galmydar, PET/MRI, 18F-FDG - Lymphoma Cancer, Breast Cancer | Phase 1 | Not yet recruiting | Washington University School of Medicine | 36 | 2026-11-01 | 2026-09-24 |
| Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI, Exercise Mobilized Therapeutic DLI - Acute Lymphoid Leukemia, Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | University of Arizona | 94 | 2026-10-31 | 2026-07-13 |
| Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma Therapeutic Hydrocortisone, Cytarabine, Dexamethasone - Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 59 | 2026-09-25 | 2026-10-02 |
| BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies LMY-922 - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Not yet recruiting | Luminary Therapeutics | 27 | 2026-09-01 | 2026-07-01 |
| Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) Non-Hodgkin Lymphoma, T-Cell Lymphoma | Recruiting | Natera, Inc. | 200 | 2026-07-27 | 2026-08-06 | |
| Identification of the Best Treatment Pathway for Patients With Relapsed/Refractory Lymphocytic B-derived Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma | Not yet recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 70 | 2026-06-30 | 2026-05-29 | |
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 46 | 2026-05-08 | 2026-07-28 |
| GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL GB5005 CART - Non-hodgkin Lymphoma, Refractory Lymphoma | Phase 1 | Recruiting | The First Affiliated Hospital of Xiamen University | 45 | 2026-04-30 | 2026-03-13 |
| Cord Blood Transplantation in Children and Young Adults With Blood Cancer Cord Blood Units, Total Body Irradiation, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 71 | 2026-04-28 | 2026-05-14 |
| A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy Audio Tasks - Non-hodgkin Lymphoma, Multiple Myeloma | Recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2026-04-17 | 2026-10-13 | |
| Halt Aging in Survivors of Blood Cancers Behavioral Coaching Intervention, Virtual Exercise Platform - Hematological Malignancy, Leukemia | Not applicable | Recruiting | University of Nebraska | 180 | 2026-04-09 | 2026-07-01 |
| PIC1 Injection Therapy for Relapsed/Refractory B-NHL PIC1 Injection - Non-Hodgkin Lymphoma | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 18 | 2026-03-01 | 2026-03-06 |
| A Phase I Study of JLM019 Injection JLM019 Injection - Advanced Solid Tumor (Phase 1), Hodgkin Lymphoma | Phase 1 | Recruiting | Jecho Biopharmaceuticals Co., Ltd. | 115 | 2026-01-13 | 2026-06-03 |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel - Large B-cell Lymphoma, Lymphoma, B-Cell | Phase 3 | Recruiting | Lyell Immunopharma, Inc. | 400 | 2026-01-12 | 2026-08-04 |
| Amping up With PemJAK Ruxolitinib, Pembrolizumab - Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma | Phase 2 | Recruiting | Seda S. Tolu | 53 | 2025-12-03 | 2025-12-16 |
| Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies LV009 Injection - Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2025-12-03 | 2025-12-16 |
| Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas C7R.CD30.CAR-EBVST cells - CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type | Phase 1 | Recruiting | Baylor College of Medicine | 90 | 2025-10-27 | 2026-10-02 |
| Mozobil for Autologous Hematopoietic Stem Cell Transplantation Plerixafor, Gcsf - Multiple Myeloma, Hodgkin Lymphoma | Phase 2 | Recruiting | Thomas Jefferson University | 100 | 2025-10-16 | 2025-11-28 |
| Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma HY004 - Non-hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | Juventas Cell Therapy Ltd. | 2025-09-01 | 2025-08-08 |
Showing 20 of 297. Sign in to see all of them.
Lymphoma, Non-Hodgkin (297) · Hodgkin Disease (91) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (63) · Leukemia, Lymphocytic, Chronic, B-Cell (58) · Multiple Myeloma (54) · Lymphoma (50) · Myelodysplastic Syndromes (49) · Leukemia, Myeloid, Acute (48) · Lymphoma, Follicular (41) · Lymphoma, Large B-Cell, Diffuse (39) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (31) · Lymphoma, Mantle-Cell (30) · Lymphoma, B-Cell (26) · Lymphoma, B-Cell, Marginal Zone (22) · Neoplasms (20)
Hemic and Lymphatic Diseases (297) · Immunoproliferative Disorders (296) · Neoplasms by Histologic Type (296) · Immune System Diseases (295) · Lymphatic Diseases (295) · Lymphoproliferative Disorders (293) · Neoplasms (277) · Lymphoma (247) · Hematologic Diseases (143) · Leukemia (100) · Pathological Conditions, Signs and Symptoms (99) · Leukemia, Lymphoid (97) · Pathologic Processes (95) · Disease Attributes (89) · Chronic Disease (75)
Cyclophosphamide (36) · Rituximab (25) · fludarabine (20) · fludarabine phosphate (16) · Whole-Body Irradiation (13) · Etoposide (12) · Mycophenolic Acid (12) · Melphalan (9) · Prednisone (9) · venetoclax (9) · Busulfan (8) · Lenalidomide (8) · Cyclosporine (7) · Doxorubicin (7) · Granulocyte Colony-Stimulating Factor (7)
National Cancer Institute (NCI) (13) · Baylor College of Medicine (10) · City of Hope Medical Center (9) · Fred Hutchinson Cancer Center (8) · Memorial Sloan Kettering Cancer Center (7) · Masonic Cancer Center, University of Minnesota (6) · M.D. Anderson Cancer Center (5) · Washington University School of Medicine (5) · Hoffmann-La Roche (4) · St. Jude Children's Research Hospital (4) · AstraZeneca (3) · Case Comprehensive Cancer Center (3) · Genmab (3) · Massachusetts General Hospital (3) · Mayo Clinic (3)
United States (211) · China (35) · Germany (24) · France (23) · Italy (23) · Australia (22) · Spain (19) · South Korea (18) · United Kingdom (15) · Canada (14) · Japan (14) · Israel (8) · Netherlands (8) · Poland (8) · Switzerland (7)
Carlos A Ramos, MD (3) · Christopher J Melani, M.D. (3) · Helen Heslop, MD (3) · Ryotaro Nakamura, MD (3) · Gregory Hale, M.D. (2) · Leona Holmberg (2) · Mitchell Cairo, MD (2)
PMID 34515338, PMID 40156952, PMID 18981007, PMID 19508716, PMID 19636010, PMID 20530284, PMID 20697067, PMID 21706316, PMID 21841163, PMID 22045986, PMID 22067707, PMID 22169408, PMID 22504934, PMID 24573552, PMID 24782509, PMID 24869942, PMID 25135998, PMID 25319501, PMID 25612623, PMID 26639348, PMID 26729448, PMID 27354476, PMID 27760761, PMID 27771496, PMID 27831501, PMID 28278727, PMID 28490569, PMID 28588018, PMID 28903943, PMID 29141948, PMID 29218366, PMID 29444231, PMID 30522922, PMID 30937889, PMID 31023700, PMID 31154457, PMID 31395089, PMID 31401903, PMID 31471376, PMID 31476851, PMID 31518304, PMID 31609651, PMID 31685491, PMID 32023374, PMID 32040960, PMID 32499241, PMID 32556281, PMID 32701411, PMID 32871584, PMID 32877524
2023 (5), P30CA015704 (5), P30CA033572 (5), 2015 (4), 2005 (2), 2016 (2), 2017 (2), 2018 (1), 4UL1TR000427-10 (1), 5UG1CA189824 (1), K07CA136966 (1), K12CA167540 (1), P01CA018029 (1), P01CA078902 (1), P01CA229997 (1)